Table 3 Cumulative incidence of adverse events (AEs) in the safety population by study week
Donepezil 23–23 | Donepezil 10–23 | |||||||
|---|---|---|---|---|---|---|---|---|
N = 570 | N = 332 | |||||||
1 week | 2 weeks | 4 weeks | 52 weeks (total duration) | 1 week | 2 weeks | 4 weeks | 52 weeks (total duration) | |
Patients with at least 1 AE, % | 15.8 | 18.6 | 23.2 | 72.8 | 20.8 | 25.9 | 31.9 | 78.0 |
Patients who discontinued due to AEs, % | 0.5 | 1.6 | 2.3 | 11.4 | 2.4 | 3.9 | 4.8 | 17.5 |
Patients with AEs, % | ||||||||
Diarrhea | 0.4 | 0.4 | 0.9 | 3.5 | 1.5 | 2.1 | 2.7 | 5.7 |
Nausea | 0.2 | 0.2 | 0.2 | 2.1 | 3.9 | 4.2 | 4.2 | 6.0 |
Vomiting | 0.0 | 0.0 | 0.0 | 1.6 | 2.4 | 2.4 | 2.7 | 4.5 |
Dizziness | 0.4 | 0.4 | 0.5 | 1.1 | 0.9 | 1.2 | 1.5 | 3.6 |